433 related articles for article (PubMed ID: 11511820)
1. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor.
Rakotoambinina B; Médioni J; Rabian C; Jubault V; Jais JP; Viard JP
J Acquir Immune Defic Syndr; 2001 Aug; 27(5):443-9. PubMed ID: 11511820
[TBL] [Abstract][Full Text] [Related]
2. Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study.
Guaraldi G; Zona S; Orlando G; Carli F; Stentarelli C; Luzi K; Garlassi E; Menozzi M; Bagni P; Adorni F
Clin Drug Investig; 2011 Nov; 31(11):759-67. PubMed ID: 21919542
[TBL] [Abstract][Full Text] [Related]
3. Clinical lipoatrophy in HIV-1 patients on HAART is not associated with increased abdominal girth, hyperlipidaemia or glucose intolerance.
Worm D; Kirk O; Andersen O; Vinten J; Gerstoft J; Katzenstein TL; Nielsen H; Pedersen C
HIV Med; 2002 Oct; 3(4):239-46. PubMed ID: 12444941
[TBL] [Abstract][Full Text] [Related]
4. Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART).
Vigouroux C; Gharakhanian S; Salhi Y; Nguyen TH; Chevenne D; Capeau J; Rozenbaum W
Diabetes Metab; 1999 Sep; 25(3):225-32. PubMed ID: 10499191
[TBL] [Abstract][Full Text] [Related]
5. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study.
Martinez E; Mocroft A; García-Viejo MA; Pérez-Cuevas JB; Blanco JL; Mallolas J; Bianchi L; Conget I; Blanch J; Phillips A; Gatell JM
Lancet; 2001 Feb; 357(9256):592-8. PubMed ID: 11558485
[TBL] [Abstract][Full Text] [Related]
6. HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study.
Carr A; Hudson J; Chuah J; Mallal S; Law M; Hoy J; Doong N; French M; Smith D; Cooper DA;
AIDS; 2001 Sep; 15(14):1811-22. PubMed ID: 11579243
[TBL] [Abstract][Full Text] [Related]
7. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy.
Barreiro P; Soriano V; Blanco F; Casimiro C; de la Cruz JJ; González-Lahoz J
AIDS; 2000 May; 14(7):807-12. PubMed ID: 10839588
[TBL] [Abstract][Full Text] [Related]
8. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.
Carr A; Miller J; Law M; Cooper DA
AIDS; 2000 Feb; 14(3):F25-32. PubMed ID: 10716495
[TBL] [Abstract][Full Text] [Related]
9. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
[TBL] [Abstract][Full Text] [Related]
10. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study.
Saint-Marc T; Partisani M; Poizot-Martin I; Rouviere O; Bruno F; Avellaneda R; Lang JM; Gastaut JA; Touraine JL
AIDS; 2000 Jan; 14(1):37-49. PubMed ID: 10714566
[TBL] [Abstract][Full Text] [Related]
11. Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study).
Ribera E; Paradiñeiro JC; Curran A; Sauleda S; García-Arumí E; Castella E; Puiggròs C; Crespo M; Feijoo M; Diaz M; Del Saz SV; Planas M; Sureda D; Falcó V; Ocaña I; Pahissa A
HIV Clin Trials; 2008; 9(6):407-17. PubMed ID: 19203906
[TBL] [Abstract][Full Text] [Related]
12. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population.
Lichtenstein KA; Ward DJ; Moorman AC; Delaney KM; Young B; Palella FJ; Rhodes PH; Wood KC; Holmberg SD;
AIDS; 2001 Jul; 15(11):1389-98. PubMed ID: 11504960
[TBL] [Abstract][Full Text] [Related]
13. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.
Carr A; Samaras K; Burton S; Law M; Freund J; Chisholm DJ; Cooper DA
AIDS; 1998 May; 12(7):F51-8. PubMed ID: 9619798
[TBL] [Abstract][Full Text] [Related]
14. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
[TBL] [Abstract][Full Text] [Related]
15. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
[TBL] [Abstract][Full Text] [Related]
16. Self-reported signs of lipodystrophy by persons living with HIV infection.
Dreezen C; Schrooten W; de Mey I; Goebel FD; Dedes N; Florence E; Colebunders R;
Int J STD AIDS; 2002 Jun; 13(6):393-8. PubMed ID: 12015013
[TBL] [Abstract][Full Text] [Related]
17. Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+ -lymphocyte count and CD4+ -lymphocyte percentage at baseline and use of protease inhibitors and stavudine.
Arpadi SM; Cuff PA; Horlick M; Wang J; Kotler DP
J Acquir Immune Defic Syndr; 2001 May; 27(1):30-4. PubMed ID: 11404517
[TBL] [Abstract][Full Text] [Related]
18. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection.
van der Valk M; Gisolf EH; Reiss P; Wit FW; Japour A; Weverling GJ; Danner SA;
AIDS; 2001 May; 15(7):847-55. PubMed ID: 11399957
[TBL] [Abstract][Full Text] [Related]
19. Lipodystrophy in 685 HIV-1-treated patients: influence of antiretroviral treatment and immunovirological response.
Boufassa F; Dulioust A; Lascaux AS; Meyer L; Boué F; Delfraissy JF; Sobel A; Goujard C
HIV Clin Trials; 2001; 2(4):339-45. PubMed ID: 11590538
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
